With over nine years of laboratory experience, I have played a key role in launching three research labs and driving projects across structural biology, cancer research, and drug resistance. My research journey began with a master’s thesis on HIV reverse transcriptase, where I developed a cost-effective, structure-based computational approach to predict treatment-resistant mutations. This work included molecular dynamics simulations and X-ray crystallography at Brookhaven National Laboratory, igniting my interest in protein structure and drug interactions.In the Keedy Lab, I focused on understanding protein flexibility and allosteric regulation in Protein Tyrosine Phosphatases—critical targets in diseases such as cancer and diabetes. My approach combined crystallography, computational modeling, and biophysical assays to identify potential allosteric drug-like molecules.Currently, in the Mahajan Lab, I lead translational cancer research on osteosarcoma, investigating the role of EGR1 and KRAS mutations in Riluzole-induced apoptosis and drug resistance. I apply molecular and biochemical techniques—including qPCR, Western blotting, and chromatin immunoprecipitation—to develop combination drug strategies and support in vivo studies. My work contributes to a deeper understanding of treatment resistance mechanisms and informs potential therapeutic interventions.